DUKE UNIVERSITY
- Unique Entity ID (UEI)
- TP7EK8DZV6N5
- Parent company
- DUKE UNIVERSITY (this vendor is its own parent)
- Registered address
- DURHAM, NC, district NC-04
- Other names on record
- DUKE UNIVERSITY; DUKE UNIVERSITY HEALTH SYSTEM INC.; DUKE UNIVERSITY HOSPITAL; DUKE UNIVERSITY MEDICAL CENTER; DUKE UNIVERSITY PRESS; DUKE UNIVERSITY, MEDICAL SCHOOL; DUKE UNIVERSITY, TRINITY COLLEGE OF ARTS & SC; PRIVATE DIAGNOSTIC CLINIC PLLC; UNIVERSITY OF MARYLAND BALTIMORE PROFESSIONAL
Dollars are contract obligations in the fiscal year, as USAspending adds them up from each award's transactions. A contract's full value can be larger and run over several years. A figure below zero is money taken back from contracts signed earlier.
Source: USAspending.gov, the Treasury’s public record of federal spending. Our copy was saved November 19, 2026.
Which agencies pay this vendor, and where the work is done
Fiscal year 2027: $3,646.89
| Agency | Contract dollars |
|---|---|
| National Aeronautics and Space Administration | $41,666.67 |
| Department of Veterans Affairs | -$14,608 |
| Department of Health and Human Services | -$23,411.78 |
| District where the work is done | Contract dollars |
|---|---|
| NC-04Valerie P. Foushee | $3,646.89 |
Fiscal year 2026: $58,203,851.54
| Agency | Contract dollars |
|---|---|
| Department of Health and Human Services | $55,423,368.48 |
| Department of Defense | $1,524,952.62 |
| Department of Veterans Affairs | $780,387 |
| National Aeronautics and Space Administration | $461,172 |
| Department of Agriculture | $30,012 |
| Department of the Interior | -$16,040.56 |
| District where the work is done | Contract dollars |
|---|---|
| NC-04Valerie P. Foushee | $56,928,541.54 |
| MD-08Jamie Raskin | $1,256,810 |
| NC-09Richard Hudson | $18,500 |
| CA-19Jimmy Panetta | $0 |
| MD-04Glenn Ivey | $0 |
Largest awards
The largest contract awards with activity from October 1, 2025 to September 30, 2027, by each award's total amount over its whole life. 1 rows of the answer belong to related companies and are left out.
| Award | Agency | Where the work is done | Award total | Start |
|---|---|---|---|---|
| 75N93019C00053COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $77,629,981.68 | Ends September 30, 2029 |
| 75N93019C00050THIS CONTRACT WILL SUPPORT COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $67,973,442.64 | Ends July 28, 2027 |
| HHSN272201700061CIGF::OT::IGF EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY (EQAPOL) | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $35,846,627.14 | Ends September 29, 2024 |
| 75N93019C00054COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) - COMPONENT C: CLINICAL CORE (AWARDED POP: SEPTEMBER 16, 2019 - SEPTEMBER 15, 2020) | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $35,619,447.24 | Ends December 31, 2030 |
| 75R60220C00008NATIONAL CORD BLOOD INVENTORY | Department of Health and Human ServicesHealth Resources and Services Administration | DURHAM, NC-04 | $31,016,848 | Ends September 3, 2036 |
| 75N93019C00015IGF::OT::IGF NIAID VIROLOGY QUALITY ASSURANCE (VQA) | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $24,039,431.64 | Ends June 20, 2026 |
| 75N93022C00055"ADVANCED DEVELOPMENT OF A NEUTRALIZING ANTIBODY VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES" | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $18,032,120.76 | Ends May 31, 2028 |
| HHSN272201800004CIGF::OT::IGF NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $17,977,569.61 | Ends March 29, 2025 |
| 75N93024F00001EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY (EQAPOL) | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $12,075,641 | Ends September 29, 2027 |
| 75N93021C00010IMMUNOLOGY QUALITY ASSESSMENT (IQA) PROGRAM | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $10,850,735.53 | Ends September 29, 2027 |
| 75N94023F00004BPCA INNOVATIVE TRIAL DESIGNS AND ASSAY DEVELOPMENTS IN PEDIATRIC THERAPEUTICS | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $8,783,682 | Ends September 27, 2027 |
| 75N93022C00053ADJUVANT COMPARISON AND CHARACTERIZATION | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $8,457,032 | Ends April 30, 2028 |
| 75N94026F00002NICHD: R&D: BESPOKE GENE THERAPY CONSORTIUM (BGTC) - SUPPORT FOR NIH-SPONSORED CLINICAL TRIALS: NON-SEVERABLE | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $8,301,883 | Ends September 27, 2030 |
| 75N94019F00126TO PROVIDE A PLATFORM FOR THE INCLUSION OF PATIENTS WITH DOWN SYNDROME INTO THE PHARMACOLOGY-BASED CLINICAL TRIALS. THE GOALS ARE TO RECRUIT THIS PATIENT POPULATION INTO THE PEDIATRIC TRIALS NETWORK OPPORTUNISTIC STUDY MODEL AND TO DEVELOP A TRAINING | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $6,796,097.55 | Ends July 31, 2026 |
| 75N93023F00001THE PURPOSE OF THIS TASK ORDER IS TO (A) ACQUIRING, PROCURING AND/OR MANUFACTURING MATERIALS REQUIRED FOR THE GENERATION OF A SCALABLE IN VITRO TRANSCRIPTION (IVT) REACTION, THE PURIFICATION OF THE TRANSCRIBED MRNA, PROCUREMENT/SYNTHESIS OF LIPID RAW | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $6,769,527 | Ends March 28, 2027 |
| HHSN272201800003CIGF::OT::IGF NONHUMAN PRIMATE CORE VIROLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $6,148,488.27 | Ends December 14, 2024 |
| 75N93024F00001FEASIBILITY FOR DEVELOPMENT OF A LIPOSOME/LNP DISPLAYING AN HIV ENV TRIMER PROTEIN AND CONTAINING/INCORPORATING AN MRNA | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $5,885,384 | Ends August 27, 2028 |
| 75N94026F00001NICHD: R&D: INNOVATIVE TRIAL DESIGNS AND LABS 2.0: NON-SEVERABLE | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $5,699,498 | Ends June 28, 2030 |
| 75N93025C00006NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $5,120,519 | Ends March 29, 2027 |
| 140D0422P0227THIS ACQUISITION IS FOR COMMERCIAL OPERATION AND MAINTENANCE SUPPORT SERVICES FOR THE NATIONAL DATA ARCHIVE ON CHILD ABUSE AND NEGLECT (NDACAN) DATABASE. THE ACF IS THE AGENCY WITHIN HHS THAT IS RESPONSIBLE FOR FEDERAL PROGRAMS THAT PROMOTE THE ECONO | Department of the InteriorDepartmental Offices | DURHAM, NC-04 | $5,011,416.82 | Ends September 29, 2026 |
| 75N94025F00002NICHD: R&D: BPCA PEDIATRIC DRUG DEVELOPMENT CLINICAL TRIAL INFRASTRUCTURE: SEVERABLE | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $4,996,765.70 | Ends September 19, 2027 |
| 75N94025F00001NICHD: R&D: BEST PHARMACEUTICALS FOR CHILDREN ACT (BPCA) PEDIATRIC TRIALS NETWORK (PTN): CORE FUNCTION ACTIVITIES - THE CONTRACTOR SHALL ESTABLISH AND MAINTAIN CENTRALIZED TEAMS OF EXPERTS WHO WILL DEVELOP PROTOCOLS AND INFORMED CONSENT FORMS AND | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $4,790,048 | Ends June 3, 2027 |
| 75N93024C00074INNOVATIONS IN FUNCTIONAL B CELL EPITOPE DISCOVERY | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $4,602,385 | Ends September 29, 2027 |
| 75N94021F00003PHARMACEUTICALS (PK) AND SAFETY OF COMMONLY USED DRUGS IN LACTATING WOMEN AND BREASTFED INFANTS (CUDDLE 2.0) NETWORK | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $3,938,833.11 | Ends June 30, 2026 |
| 75N93024C00005PROMOTING T CELL RECOVERY AFTER RADIATION INJURY WITH LONG-ACTING INTERLEUKIN 7 | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $3,499,087 | Ends February 28, 2027 |
| 75N93026C00005VIROLOGY QUALITY ASSURANCE (VQA) | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $3,408,692 | Ends June 20, 2027 |
| 75N93022F00001RESEARCH AND DEVELOPMENT PRODUCT STORAGE AND SHIPPING | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $2,889,750 | Ends November 30, 2026 |
| 75N94021F00001BPCA PHARMACOEPIDEMIOLOGY (REAL WORLD DATA) STUDIES | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $2,394,451.92 | Ends May 31, 2026 |
| 75N93019F001311500006I DUKE UNIVERSITY; TO 18-0006.B1.0115--06 BASE AWARD; BIOD CAN 8470038 $55,158 | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $2,360,364.60 | Ends July 31, 2025 |
| 36C24623P1586BRAIN TISSUE PROCESSING WITH DUKE UNIVERSITY | Department of Veterans Affairs | DURHAM, NC-04 | $2,328,225.57 | Ends September 12, 2027 |
| 75D30123F000022023 CLINICAL IMMUNIZATION SAFETY ASSESSMENT (CISA) BASE IDIQ | Department of Health and Human ServicesCenters for Disease Control and Prevention | DURHAM, NC-04 | $2,171,300 | Ends May 31, 2027 |
| W912HQ22C0057RC20-3054 FY21 SERDP FUNDS, $100,000.00 | Department of DefenseDepartment of the Army | DURHAM, NC-04 | $1,999,772 | Ends June 19, 2027 |
| 75N93025C00002VIROLOGY CORE LABORATORY | Department of Health and Human ServicesNational Institutes of Health | DURHAM, NC-04 | $1,876,865 | Ends December 14, 2026 |
| 75D30126F00004CISA HOME LAIV STUDY- LEAD SITE, EO 14398 | Department of Health and Human ServicesCenters for Disease Control and Prevention | DURHAM, NC-04 | $1,869,870 | Ends September 27, 2029 |
| 75F40123C00209A STUDY IN MEDICARE ADVANTAGE FOR REAL WORLD EVIDENCE IN CARDIOVASCULAR DISEASE | Department of Health and Human ServicesFood and Drug Administration | SILVER SPRING, MD-08 | $1,567,108 | Ends June 28, 2027 |
| 75D30124F00003CISA RSV INFANTS STUDY (LEAD SITE) | Department of Health and Human ServicesCenters for Disease Control and Prevention | DURHAM, NC-04 | $1,532,777.65 | Ends September 26, 2027 |
| 75F40126C00112EO14398 - BROAD AGENCY ANNOUNCEMENT (BAA) FY26C1IP3 - ADVANCED RESEARCH AND DEVELOPMENT OF REGULATORY SCIENCE - CORE CLINICAL OUTCOME ASSESSMENT GRANT PROGRAM | Department of Health and Human ServicesFood and Drug Administration | DURHAM, NC-04 | $1,456,427 | Ends September 29, 2028 |
| 75F40120C00179BAA: QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUP | Department of Health and Human ServicesFood and Drug Administration | DURHAM, NC-04 | $1,439,896.36 | Ends June 30, 2024 |
| 7571MN26C00048NATIONAL DATA ARCHIVE ON CHILD ABUSE AND NEGLECT (NDACAN) OPERATIONS AND MAINTENANCE (O&M) SERVICES FOR ACF/CB THIS IS A DOI CONTRACT #140D0422P0227, THAT IS TRANSFERRED TO HHS/ASFR/OMAS. | Department of Health and Human ServicesOffice of the Assistant Secretary for Financial Resources | DURHAM, NC-04 | $1,395,988.27 | Ends September 29, 2027 |
| 75F40126C00181FIRM FIXED PRICE AWARD TOWARDS ML-POWERED, EFFICIENT AND ROBUST INFERENCE OF AVERAGE AND INDIVIDUAL TREATMENT EFFECTS FOR NOVEL CLINICAL TRIALS IN RARE DISEASES CONTRACTING OFFICER REPRESENTATIVE: DEBORAH ELLIOTT TELEPHONE: (240) 397-3022 DEBO | Department of Health and Human ServicesFood and Drug Administration | SILVER SPRING, MD-08 | $1,256,810 | Ends September 29, 2030 |
Subcontracts it reported
A prime contractor reports the subcontracts it gives under an award (first-tier subawards). These are the largest it reported under its three largest awards, from every year of each award.
Under award 75N93019C00050
| Subcontractor | What it is for, as reported | Amount | Date |
|---|---|---|---|
| TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | ANTIGEN DEVELOPMENT WILL BE DIVIDED INTO 2 PARTS. THE FIRST WILL DEVELOP UNIVERSAL VACCINE IMMUNOGENS. THIS INCLUDES THE OPTIMIZATION OF EACH IMMUNOGEN MRNA FOR PEAK TRANSLATION AND IMMUNOGENICITY AND LACK OF INNATE IMMUNE ACTIVATION. NEXT, MRNA€Ͽ½LNP DELIVERY ROUTES WILL BE EXPLORED TO DEVELOP | $1,512,029 | |
| TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | ANTIGEN DEVELOPMENT WILL BE DIVIDED INTO 2 PARTS. THE FIRST WILL DEVELOP UNIVERSAL VACCINE IMMUNOGENS. THIS INCLUDES THE OPTIMIZATION OF EACH IMMUNOGEN MRNA FOR PEAK TRANSLATION AND IMMUNOGENICITY AND LACK OF INNATE IMMUNE ACTIVATION. NEXT, MRNA€Ͽ½LNP DELIVERY ROUTES WILL BE EXPLORED TO DEVELOP | $1,499,639 | |
| CHILDREN'S HOSPITAL CORPORATION, THE | THE IMMUNOGEN DESIGN AND IMMUNE-RESPONSE EVALUATION DISCOVERY GROUP, LED BY STEPHEN C. HARRISON (BOSTON CHILDREN'S HOSPITAL, HARVARD MEDICAL SCHOOL; HHMI) AND AARON G. SCHMIDT (RAGON INSTITUTE OF HARVARD, MIT AND MASSACHUSETTS GENERAL HOSPITAL; HARVARD MEDICAL SCHOOL), WILL BUILD ON STRUCTURAL STUDI | $424,927 | |
| CHILDREN'S HOSPITAL CORPORATION, THE | THE IMMUNOGEN DESIGN AND IMMUNE-RESPONSE EVALUATION DISCOVERY GROUP, LED BY STEPHEN C. HARRISON (BOSTON CHILDREN'S HOSPITAL, HARVARD MEDICAL SCHOOL; HHMI) AND AARON G. SCHMIDT (RAGON INSTITUTE OF HARVARD, MIT AND MASSACHUSETTS GENERAL HOSPITAL; HARVARD MEDICAL SCHOOL), WILL BUILD ON STRUCTURAL STUDI | $424,927 | |
| THE GENERAL HOSPITAL CORPORATION | DR. AARON G. SCHMIDT AT MASSACHUSETTS GENERAL HOSPITAL WILL BE A PARTICIPANT IN THIS DUKE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER (CIVIC) AS ONE OF THE INFLUENZA ANTIGEN DISCOVERY TEAMS. DR. SCHMIDT AND HIS TEAM WILL DESIGN AND SELECT HEMAGGLUTININ-BASED IMMUNOGENS THAT WILL BE TRANSFERRED | $424,585 | |
| THE GENERAL HOSPITAL CORPORATION | DR. AARON G. SCHMIDT AT MASSACHUSETTS GENERAL HOSPITAL WILL BE A PARTICIPANT IN THIS DUKE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER (CIVIC) AS ONE OF THE INFLUENZA ANTIGEN DISCOVERY TEAMS. DR. SCHMIDT AND HIS TEAM WILL DESIGN AND SELECT HEMAGGLUTININ-BASED IMMUNOGENS THAT WILL BE TRANSFERRED | $424,585 | |
| TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | CIVICS A OPTION 22A PRECLINICAL TESTING OF 20 HA MRNA-LNP VACCINE | $384,749 | |
| TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | OPTION 23E €€Œ THE HENSLEY LABORATORY WILL DEVELOP MRNA VACCINES EXPRESSING MULTIPLE H3N2 AND H1N1 ANTIGENS, SPECIFICALLY, MULTIVALENT H3 VACCINES EXPRESSING HAS FROM 3C2.A AND 3C.3 LINEAGES AND MULTIVALENT H1 VACCINES EXPRESSING HAS FROM PRE-2009 H1N1 STRAINS AND CONTEMPORARY H1N1 STRAINS. THE | $384,749 | |
| UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | THIS WORK WILL ADVANCE THE HA€Ͽ½ELS PLATFORM AS A POTENTIAL SUPRA€Ͽ½SEASONAL OR PAN€Ͽ½SEROTYPE VACCINE. | $384,749 | |
| NAJIT TECHNOLOGIES, INC. | THE OVERALL GOAL IS TO USE A STRUCTURE-BASED APPROACH TO DEVELOP NEW AND IMPROVED FLU VACCINES BY UTILIZING THE NOVEL HYDROVAX‎¢ VACCINE PLATFORM. | $384,430 |
More subcontracts are reported under this award; the 10 largest are listed.
Under award HHSN272201700061C
| Subcontractor | What it is for, as reported | Amount | Date |
|---|---|---|---|
| VITALANT | INITATE CONTACT, SECURE PARTICIPATION AGREEMENTS AND SERVE AS THE PRIMARY STUDY CONTRACT FOR 6 TARGETED INTERNAL COLLABORATORS A YEAR | $223,458 | |
| GEORGE WASHINGTON UNIVERSITY (THE) | EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY | $183,889 | |
| GEORGE WASHINGTON UNIVERSITY (THE) | PROVIDE A STABILIZED FRAMEWORK FOR EQAPOL SCIENTISTS TO ANALYZE HIV-1 DATA. HIVE TOOLS WILL BE ADAPTED AND ANY NEW PUBLICLY AVAILABLE TOOLS NEEDED FOR ANALYSIS WILL BE INTEGRATED INTO HIVE. | $96,102 |
Lobbying reports and campaign receipts that name this vendor
A name is matched only when it is the same name under the exact-name rule: letters and numbers alike, "&" read as "and", a leading "the" and one closing legal form (Inc, LLC, Corp, Corporation, Co, LP, LLP) set aside. A near name is never a match. Each match says which name matched.
Lobbying reports that name DUKE UNIVERSITY
How it matched: vendor name, exact name: the name in the lobbying report as client.
| Registrant | Client | Amount for the whole quarter | Quarter | Filed | Report |
|---|---|---|---|---|---|
| DLA PIPER LLP (US) | DUKE UNIVERSITY | $80,000reported as income | Third quarter of 2026 | Open the report | |
| DUKE UNIVERSITY | DUKE UNIVERSITY | $201,000reported as expenses | Third quarter of 2026 | Open the report |
FEC receipts that name DUKE UNIVERSITY as the employer
How it matched: vendor name, exact name, as the employer of itemized receipts from individuals (FEC).
- Deborah K. Ross: 1 itemized receipt, $3,500
Only the 25 largest itemized receipts of each committee are saved, so this counts those receipts and no others. An employer is the contributor's own answer on the form.